PTC Therapeutics, Inc. Proceeds from Sale of Debt Securities, Available-for-sale
PTC Therapeutics, Inc. (PTCT) reported Proceeds from Sale of Debt Securities, Available-for-sale of $709.33 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt · last filed 2026-07-30
- PTC Therapeutics, Inc. proceeds from sale of debt securities, available-for-sale for the quarter ending 2026-06-30 was $332.97M, a 201.60% increase year-over-year.
- PTC Therapeutics, Inc. proceeds from sale of debt securities, available-for-sale for the quarter ending 2026-03-31 was $376.36M, a 175.22% increase year-over-year.
- PTC Therapeutics, Inc. proceeds from sale of debt securities, available-for-sale for the quarter ending 2025-12-31 was $359.55M, a 38.94% increase year-over-year.
- PTC Therapeutics, Inc. proceeds from sale of debt securities, available-for-sale for the quarter ending 2025-09-30 was $177.20M, a 14.93% increase year-over-year.
- PTC Therapeutics, Inc. proceeds from sale of debt securities, available-for-sale for fiscal 2025 was $783.90M, a 42.63% increase from fiscal 2024.
- PTC Therapeutics, Inc. proceeds from sale of debt securities, available-for-sale for fiscal 2024 was $549.61M, a 2451.10% increase from fiscal 2023.
- PTC Therapeutics, Inc. proceeds from sale of debt securities, available-for-sale for fiscal 2023 was $21.54M, a 94.68% decline from fiscal 2022.
- PTC Therapeutics, Inc. proceeds from sale of debt securities, available-for-sale for fiscal 2022 was $405.23M, a 51.96% decline from fiscal 2021.
| Period end | Proceeds from Sale of Debt Securities, Available-for-sale 3 month | Proceeds from Sale of Debt Securities, Available-for-sale 6 month | Proceeds from Sale of Debt Securities, Available-for-sale 9 month | Proceeds from Sale of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $332.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $709.33M 10-Q · filed 2026-07-30 | $1.07B derived: sum of 3 quarters · filed 2026-07-30 | $1.25B derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $376.36M 10-Q · filed 2026-05-07 | $735.90M derived: sum of 2 quarters · filed 2026-05-07 | $913.10M derived: sum of 3 quarters · filed 2026-05-07 | $1.02B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $359.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $536.75M derived: sum of 2 quarters · filed 2026-02-19 | $647.15M derived: sum of 3 quarters · filed 2026-07-30 | $783.90M 10-K · filed 2026-02-19 |
| 2025-09-30 | $177.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $287.60M derived: sum of 2 quarters · filed 2026-07-30 | $424.35M 10-Q · filed 2025-11-04 | $683.12M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $110.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $247.15M 10-Q · filed 2026-07-30 | $505.92M derived: sum of 3 quarters · filed 2026-07-30 | $660.11M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $136.75M 10-Q · filed 2026-05-07 | $395.52M derived: sum of 2 quarters · filed 2026-05-07 | $549.71M derived: sum of 3 quarters · filed 2026-05-07 | $624.71M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $258.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $412.96M derived: sum of 2 quarters · filed 2026-02-19 | $487.96M derived: sum of 3 quarters · filed 2026-02-19 | $549.61M 10-K · filed 2026-02-19 |
| 2024-09-30 | $154.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $229.19M derived: sum of 2 quarters · filed 2025-11-04 | $290.84M 10-Q · filed 2025-11-04 | $290.84M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $75.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $136.65M 10-Q · filed 2025-08-07 | $136.65M derived: sum of 3 quarters · filed 2026-02-19 | $136.65M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $61.65M 10-Q · filed 2025-05-06 | $61.65M derived: sum of 2 quarters · filed 2026-02-19 | $61.65M derived: sum of 3 quarters · filed 2026-02-19 | $70.69M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $9.04M derived: sum of 3 quarters · filed 2026-02-19 | $21.54M 10-K · filed 2026-02-19 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $9.04M derived: sum of 2 quarters · filed 2024-11-07 | $21.54M 10-Q · filed 2024-11-07 | $84.79M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $9.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $21.54M 10-Q · filed 2024-08-08 | $84.79M derived: sum of 3 quarters · filed 2025-02-27 | $169.24M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $12.50M 10-Q · filed 2024-04-25 | $75.74M derived: sum of 2 quarters · filed 2025-02-27 | $160.20M derived: sum of 3 quarters · filed 2025-02-27 | $250.63M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $63.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $147.70M derived: sum of 2 quarters · filed 2025-02-27 | $238.13M derived: sum of 3 quarters · filed 2025-02-27 | $405.23M 10-K · filed 2025-02-27 |
| 2022-09-30 | $84.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $174.89M derived: sum of 2 quarters · filed 2023-10-26 | $341.99M 10-Q · filed 2023-10-26 | $492.17M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $90.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $257.53M 10-Q · filed 2023-08-03 | $407.71M derived: sum of 3 quarters · filed 2024-02-29 | $586.32M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $167.10M 10-Q · filed 2023-04-27 | $317.28M derived: sum of 2 quarters · filed 2024-02-29 | $495.88M derived: sum of 3 quarters · filed 2024-02-29 | $618.51M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $150.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $328.78M derived: sum of 2 quarters · filed 2024-02-29 | $451.40M derived: sum of 3 quarters · filed 2024-02-29 | $843.50M 10-K · filed 2024-02-29 |
| 2021-09-30 | $178.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $301.23M derived: sum of 2 quarters · filed 2022-10-27 | $693.32M 10-Q · filed 2022-10-27 | $936.79M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $122.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $514.72M 10-Q · filed 2022-08-04 | $758.18M derived: sum of 3 quarters · filed 2023-02-21 | $1.03B derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $392.09M 10-Q · filed 2022-05-03 | $635.56M derived: sum of 2 quarters · filed 2023-02-21 | $907.70M derived: sum of 3 quarters · filed 2023-02-21 | |
| 2020-12-31 | $243.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $515.60M derived: sum of 2 quarters · filed 2023-02-21 | $944.09M 10-K · filed 2023-02-21 | |
| 2020-09-30 | $272.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $700.63M 10-Q · filed 2021-10-28 | ||
| 2020-06-30 | $428.49M 10-Q · filed 2021-07-29 | |||
| 2019-12-31 | $156.27M 10-K · filed 2022-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |